A new economic analysis argues that accelerating Food and Drug Administration reviews could generate trillions of dollars in economic value while getting treatments to patients faster, reigniting a debate over regulatory reform versus patient safety.

The report, titled "The Multi-Trillion Dollar Opportunity in Reforming the FDA," estimates that cutting FDA effectiveness-review timelines by one year could generate more than $10 trillion in economic value. The analysis points to the roughly decade-long process it takes for drugs to move through the agency, with most of that time spent on effectiveness trials rather than safety reviews.

"FDA is charged by Congress to enhance both safety and effectiveness of new drugs," said Tomas Philipson, an economist and former acting chairman of the White House Council of Economic Advisers. "People recognize the role of the government potentially ensuring safety and consumer protection, but it's a unique role that FDA has of ensuring effectiveness."

What the Right Is Saying

Conservative economists and free-market advocates say regulatory delays impose their own costs on patients suffering from conditions that existing treatments cannot adequately address. They point to Operation Warp Speed, which delivered COVID-19 vaccines in under a year, as evidence that faster pathways are possible without sacrificing efficacy.

"I think there's a huge role for the president here to push an analogous effort to what he did with Operation Warp Speed during COVID," Philipson said. "It's equally urgent for other patient groups who don't have COVID but other diseases."

Republican policymakers have long advocated for regulatory reform as a driver of economic growth. They argue that streamlining FDA reviews would increase competition, ultimately lowering prices through market forces rather than government price controls.

The report also raises competitive concerns about China's clinical trial system, which operates faster and at lower cost. Authors warn this could shift pharmaceutical research investment away from the United States if domestic regulatory timelines remain extended.

Proposed reforms include greater use of artificial intelligence in drug reviews, faster clinical trial designs, and expanded access to "right to try" programs that allow terminally ill patients to access experimental treatments outside traditional approval pathways.

What the Left Is Saying

Progressive Democrats and patient safety advocates argue that rushing drug approvals poses unacceptable risks to public health. They point to historical examples where faster approvals led to harmful medications remaining on the market longer than safer alternatives might have been developed.

Senator Bernie Sanders, a longtime critic of pharmaceutical industry pricing, has argued that the real barrier to affordable medication is not FDA speed but corporate monopolies and lack of negotiation power. "The drug companies don't want competition because competition threatens their profits," Sanders has said repeatedly in committee hearings.

Consumer groups aligned with progressive causes warn that accelerating clinical trials could expose more patients to unproven treatments. They note that the pharmaceutical industry already spends significantly more on lobbying than any other sector, raising questions about who would benefit most from streamlined regulations.

Some Democrats have proposed alternative approaches to lowering drug costs, including allowing Medicare to negotiate prices directly and capping out-of-pocket expenses for common medications. They argue these measures address affordability without compromising safety standards established over decades.

What the Numbers Show

The FDA's own data shows average review times for new drugs range from 10 months to more than six years depending on complexity and priority designation. The median time from initial clinical trial application to final approval is approximately 8.3 years across all drug categories.

Pharmaceutical industry lobbying expenditures exceeded $300 million annually over the past five years, making it consistently the highest-spending sector in Washington. Industry representatives argue this reflects compliance costs rather than influence-seeking.

According to FDA statistics, the agency approved 19 drugs in 2024 that regulators identified as having significant clinical impact, down from a peak of 59 novel drug approvals in 2018. The number of new drug applications submitted annually has remained relatively stable at 40 to 55 over the past decade.

The Congressional Budget Office has estimated that allowing Medicare to negotiate drug prices on a limited set of medications could save approximately $450 billion over ten years, though pharmaceutical manufacturers dispute these projections.

The Bottom Line

The debate over FDA reform reflects broader tensions between regulatory efficiency and safety guarantees. Both sides agree that patients benefit when effective treatments reach the market quickly, but they diverge sharply on whether current timelines represent necessary caution or unnecessary bureaucratic delay.

What happens next depends partly on whether Congress takes up pharmaceutical legislation this session. Industry groups are expected to push for expedited review pathways while patient advocacy organizations call for maintaining current safety standards.

Watch for any executive actions on FDA reform and congressional hearings examining drug approval processes. The $10 trillion figure in the report is likely to become a reference point in those discussions, though independent economists note that such macroeconomic estimates involve significant assumptions about implementation timelines and market responses.